查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1631879

DNA 和 RNA 銀行服務市場 - 全球產業規模、佔有率、趨勢、機會和預測，按類型、應用、最終用途、地區和競爭細分，2020-2030 年

DNA & RNA Banking Services Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Application, By End Use, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 183 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球 DNA 和 RNA 銀行服務市值為 79.7 億美元，預計到 2030 年將達到 121.8 億美元，預測期內複合年成長率為 7.29%。由於研究、診斷和治療應用對遺傳物質儲存和分析的需求不斷成長，全球 DNA 和 RNA 銀行服務市場已成為生物銀行領域的關鍵部門。該市場包括保存從各種來源（包括血液、組織和唾液）收集的 DNA 和 RNA 樣本，以確保其完整性以供未來的科學調查使用。個人化醫療的發展和基因組學的進步極大地推動了對這些銀行服務的需求，因為研究人員和醫療保健專業人員尋求利用遺傳資訊來開發量身定做的治療方法並增強疾病預防策略。基因組研究資金的增加和旨在了解遺傳性疾病的措施的增加進一步刺激了市場擴張。也建立了監管機構和道德準則，以確保對遺傳材料進行負責任的管理和利用，這對於建立公眾對生物樣本庫實踐的信任至關重要。新一代定序和自動樣本處理系統等技術進步提高了 DNA 和 RNA 庫的效率和準確性，從而增強了它們對學術機構、醫院和生物技術公司的吸引力。

市場概況
預測期 2026-2030
2024 年市場規模 79.7億美元
2030 年市場規模 121.8億美元
2025-2030年複合年成長率 7.29%
成長最快的細分市場 療法
最大的市場 北美洲

主要市場促進因素

基因組研究的進展

對遺傳性疾病的認知不斷提高

生物樣本庫的技術創新

主要市場挑戰

技術進步和基礎設施成本

樣品品質與誠信管理

主要市場趨勢

生物製藥產業的發展

更加重視預防性醫療保健

細分市場洞察

類型洞察

應用洞察

區域洞察

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：客戶之聲

第 5 章：全球 DNA 與 RNA 銀行服務市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型（運輸服務、加工服務、儲存服務、品質控制服務、資料儲存、其他）
    • 按應用（治療、藥物發現和臨床研究、臨床診斷、其他）
    • 按最終用途（學術研究、製藥和生物技術公司、醫院和診斷中心、其他）
    • 按公司分類 (2024)
    • 按地區
  • 市場地圖

第 6 章：北美 DNA 與 RNA 銀行服務市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 按申請
    • 按最終用途
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第 7 章：歐洲 DNA 與 RNA 銀行服務市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 按申請
    • 按最終用途
    • 按國家/地區
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第 8 章：亞太地區 DNA 與 RNA 銀行服務市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 按申請
    • 按最終用途
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲

第 9 章：南美洲 DNA 與 RNA 銀行服務市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 按申請
    • 按最終用途
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲 DNA 和 RNA 銀行服務市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 按申請
    • 按最終用途
    • 按國家/地區
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 促進要素
  • 挑戰

第 12 章：市場趨勢與發展

  • 併購（如有）
  • 產品發布（如有）
  • 最新動態

第 13 章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 客戶的力量
  • 替代產品的威脅

第14章：競爭格局

  • DNA Genotek Inc.
  • EasyDNA
  • 23andMe, Inc.
  • Biobanking.com
  • US Biolab Corporation, Inc
  • ProteoGenex
  • Thermo Fisher Scientific, Inc.
  • deCODE genetics
  • Azenta Life Sciences
  • Infinity BiologiX LLC (Sampled).

第 15 章：策略建議

第16章調查會社について,免責事項

簡介目錄
Product Code: 25331

Global DNA & RNA Banking Services Market was valued at USD 7.97 Billion in 2024 and is expected to reach USD 12.18 Billion by 2030 with a CAGR of 7.29% during the forecast period. The Global DNA & RNA Banking Services Market has emerged as a pivotal sector in the biobanking landscape, driven by the increasing demand for genetic material storage and analysis for research, diagnostics, and therapeutic applications. This market encompasses the preservation of DNA and RNA samples collected from various sources, including blood, tissue, and saliva, ensuring their integrity for future scientific inquiries. The growth of personalized medicine and advancements in genomics have significantly propelled the demand for these banking services, as researchers and healthcare professionals seek to harness genetic information to develop tailored treatments and enhance disease prevention strategies. The rise in genomic research funding and initiatives aimed at understanding genetic disorders have further stimulated market expansion. Regulatory bodies and ethical guidelines have also been established to ensure the responsible management and utilization of genetic materials, which is essential for building public trust in biobanking practices. Technological advancements, such as next-generation sequencing and automated sample handling systems, have improved the efficiency and accuracy of DNA and RNA banking, thereby enhancing their appeal to academic institutions, hospitals, and biotechnology companies.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 7.97 Billion
Market Size 2030USD 12.18 Billion
CAGR 2025-20307.29%
Fastest Growing SegmentTherapeutics
Largest MarketNorth America

Key Market Drivers

Advancements in Genomic Research

Rapid advancements in genomic research are profoundly influencing the Global DNA & RNA Banking Services Market. The emergence of high-throughput sequencing technologies and advanced bioinformatics tools has revolutionized the ability of researchers to analyze vast amounts of genetic data quickly and efficiently. This capability is particularly crucial for understanding complex diseases, such as cancer and genetic disorders, where traditional research methods may fall short. By enabling the analysis of large-scale genomic data, these technologies facilitate the identification of genetic variations that can inform the development of targeted therapies tailored to individual patients. For instance, In January 2021, the UK launched the Rare Disease Framework, aimed at improving diagnosis, awareness, care, and treatment access for 3.5 million rare disease patients over five years. This initiative highlights the increasing demand for DNA and RNA banking services, as timely genetic analysis is essential for effective management and treatment of rare diseases.

In this evolving landscape, academic institutions and research organizations are increasingly relying on DNA and RNA banking services to secure high-quality biological samples for both ongoing and future studies. These samples serve as critical resources for research, allowing scientists to investigate the genetic underpinnings of diseases and assess potential treatment responses. The preservation of genetic material in biobanks ensures that researchers have access to diverse and representative samples, which enhances the robustness of their findings.

The trend is further supported by rising government funding and private investments in genomics research, creating a favorable environment for biobanking services. Funding initiatives are designed to support groundbreaking research projects that require access to high-quality biological materials, thereby accelerating the pace of discovery in genetic research. These investments not only facilitate the establishment of state-of-the-art biobanks but also enhance collaboration among researchers, healthcare providers, and biotechnology firms. Such collaborations foster innovation in genetic research and its applications, paving the way for new diagnostic tools and therapeutic options. The ongoing advancements in genomic research underscore the critical role of DNA and RNA banking services in the scientific community. By providing essential resources and facilitating collaboration, these services are instrumental in driving forward the frontiers of genomic knowledge and its practical applications in healthcare.

Rising Awareness of Genetic Disorders

The rising awareness of genetic disorders is emerging as a critical driver for the Global DNA & RNA Banking Services Market. As healthcare professionals and the general public become more informed about the profound impact genetics has on health, the demand for genetic testing and associated biobanking services has seen a significant uptick. This heightened awareness is fueled by various factors, including advances in medical research, increased media coverage, and educational initiatives that focus on the importance of genetics in disease prevention and management. Genetic disorders, which encompass hereditary diseases and certain types of cancer, necessitate precise genetic analysis for accurate diagnosis and effective treatment planning. For instance, according to the American Cancer Society's 2022 report, the United States is projected to see 1,918,030 new cancer cases and 609,360 cancer-related deaths in 2022, including approximately 350 daily deaths from lung cancer, the leading cause of cancer mortality. This rising incidence emphasizes the critical need for DNA and RNA banking services, as these resources are essential for advancing cancer research, enabling personalized treatment approaches, and improving outcomes for patients diagnosed with various types of cancer. As a result, hospitals, clinics, and diagnostic laboratories are increasingly utilizing DNA and RNA banking services to obtain and store samples for testing. This demand for biobanking is driven by the need for reliable and accessible genetic material, which can be used to identify mutations, assess disease risk, and guide therapeutic decisions.

The growing recognition of the importance of genetic testing emphasizes the need for robust biobanking services that ensure the integrity and quality of genetic material. Healthcare providers are now more focused on sourcing high-quality DNA and RNA samples, as these are essential for accurate test results and meaningful clinical interpretations. The presence of well-maintained biobanks enhances the capability of healthcare institutions to conduct comprehensive genetic analyses, ultimately improving patient outcomes.

Public health campaigns aimed at educating individuals about genetic risk factors and the advantages of early diagnosis are further contributing to the growing utilization of DNA and RNA banking services. These initiatives inform the public about the benefits of genetic testing in managing hereditary conditions and promoting proactive healthcare measures. Consequently, the increasing awareness of genetic disorders not only drives demand for genetic testing but also highlights the essential role of biobanking services in the healthcare ecosystem, fostering advancements in personalized medicine and enhancing patient care.

Technological Innovations in Biobanking

Technological innovations are fundamentally reshaping the Global DNA & RNA Banking Services Market, significantly enhancing the efficiency and effectiveness of biobanking operations. These advancements span various stages of biobanking, including sample collection, processing, and storage, enabling biobanks to uphold high-quality standards for genetic materials. For instance, the introduction of automated systems for sample handling and processing minimizes the risk of contamination and human error, thereby ensuring the integrity of stored samples. This level of precision is vital in maintaining the reliability of genetic materials, which is crucial for both research and clinical applications.

Next-generation sequencing (NGS) technologies have revolutionized the field of genetics by allowing for rapid and comprehensive genetic analysis. NGS provides deeper insights into genetic variations, enhancing the value of biobanked samples for a wide range of research initiatives and clinical applications. Researchers can now conduct more extensive genetic analyses, leading to discoveries that may have been unattainable with traditional sequencing methods. This capability not only accelerates research timelines but also expands the potential for novel therapeutic developments.

The integration of advanced data management systems is transforming how biobanks operate. These systems enable biobanks to efficiently organize, track, and manage samples, facilitating easier access for researchers and healthcare providers. Improved data management ensures that critical information about each sample is readily available, enhancing collaboration and expediting research projects. Robust data systems are essential for maintaining compliance with regulatory standards, thereby bolstering the credibility of biobanking operations. As these technologies continue to evolve, they are set to further streamline biobanking processes, making DNA and RNA banking services more appealing to a diverse array of potential clients, including academic institutions, hospitals, and pharmaceutical companies. The promise of enhanced efficiency, quality assurance, and data management underscores the transformative impact of technological innovations in the biobanking sector, positioning it for sustained growth and increased relevance in the broader healthcare landscape.

Key Market Challenges

Technological Advancements and Infrastructure Costs

Technological advancements in genomic research and biobanking have transformed the landscape of DNA and RNA banking services; however, they also present significant challenges, particularly concerning infrastructure costs. As new technologies, such as high-throughput sequencing and advanced bioinformatics tools, emerge, biobanks must continually upgrade their equipment and processes to stay competitive. The financial burden of implementing these technologies can be substantial, especially for smaller or emerging biobanks that may lack sufficient funding. The rapid pace of technological advancement can render existing systems obsolete, necessitating further investment in new technologies to maintain operational efficiency and data integrity. This situation creates a financial strain on biobanks, limiting their ability to invest in other critical areas such as staff training, sample quality control, and research collaboration. The integration of advanced technologies requires specialized expertise, and there is a shortage of skilled professionals in the field, which can further hinder biobanks' ability to leverage new advancements effectively. To overcome these challenges, biobanks need to develop strategic partnerships with technology providers, seek funding from governmental and private sources, and explore innovative financing models that can support ongoing technological investments while ensuring their services remain accessible and affordable.

Sample Quality and Integrity Management

Maintaining the quality and integrity of DNA and RNA samples is a critical challenge for the Global DNA & RNA Banking Services Market. The viability of genetic material is crucial for research and clinical applications, and any compromise in sample quality can lead to erroneous results and wasted resources. Various factors can impact sample integrity, including collection methods, storage conditions, and the duration of storage. For instance, improper collection techniques or inadequate storage temperatures can result in degradation of samples, rendering them unsuitable for analysis. The need for long-term storage poses unique challenges, as biobanks must implement rigorous protocols to ensure that samples remain viable over extended periods. This involves monitoring storage conditions, implementing quality control measures, and conducting regular audits to assess sample integrity. Biobanks must also address the risk of contamination, which can occur during sample handling or storage. Ensuring sample quality requires ongoing training for staff, investments in sophisticated storage systems, and adherence to best practices in sample management. Failure to maintain high standards for sample quality can undermine the credibility of biobanks and limit their ability to attract clients, ultimately impacting the growth of the DNA and RNA banking services market.

Key Market Trends

Growth of Biopharmaceutical Industry

The rapid growth of the biopharmaceutical industry is a key driver for the Global DNA & RNA Banking Services Market. In recent years, biopharmaceutical companies have become increasingly reliant on genetic research to develop novel therapeutics, including biologics and gene therapies. This shift toward precision medicine underscores the importance of understanding the genetic basis of diseases, as it enables the creation of targeted treatments that can improve patient outcomes. To achieve this, biopharmaceutical companies require access to high-quality DNA and RNA samples for their research and development activities, making biobanks invaluable resources.

Biobanks play a critical role in providing these essential resources, offering a diverse array of high-quality genetic materials that enable biopharmaceutical companies to conduct comprehensive genetic analyses. These analyses are crucial for identifying genetic markers associated with specific diseases, evaluating treatment responses, and validating findings in clinical settings. The quality and integrity of the samples provided by biobanks are paramount, as they directly impact the reliability of research outcomes and the overall success of drug development processes.

The growing trend of collaboration between biopharmaceutical companies and academic institutions for research purposes further fuels the demand for DNA and RNA banking services. These partnerships often focus on translating cutting-edge genetic research into practical therapeutic applications. By pooling resources and expertise, biopharmaceutical firms and academic researchers can advance their collective understanding of complex diseases, leading to the discovery of innovative treatment strategies. This collaborative approach highlights the need for robust biobanking services that can accommodate the specific requirements of both parties. As the biopharmaceutical industry continues to expand, it will increasingly depend on biobanking services to support its innovative research efforts. The ongoing evolution of this sector, characterized by rapid technological advancements and an increasing focus on personalized medicine, emphasizes the vital role of DNA and RNA banking services in driving the development of next-generation therapeutics and improving healthcare outcomes worldwide.

Increased Focus on Preventive Healthcare

The rising focus on preventive healthcare is a crucial driver for the Global DNA & RNA Banking Services Market. As healthcare systems worldwide transition their emphasis from reactive to preventive measures, the importance of genetic screening and risk assessment has become increasingly pronounced. This shift is largely driven by a growing understanding that many diseases have a genetic component, and early identification of genetic predispositions can lead to more effective preventive strategies. Individuals and healthcare providers are increasingly recognizing the value of understanding genetic predispositions to diseases. By identifying genetic markers associated with specific health conditions, people can make informed lifestyle choices that mitigate their risk factors. For example, individuals at higher genetic risk for conditions such as heart disease, diabetes, or certain cancers can adopt preventive measures such as dietary changes, increased physical activity, or regular health screenings. This proactive approach empowers individuals to take charge of their health, promoting a culture of prevention rather than reaction.

Consequently, the demand for DNA and RNA banking services is growing, as these services provide the necessary genetic material for risk assessment and preventive healthcare initiatives. Biobanks offer a repository of high-quality DNA and RNA samples that can be utilized in genetic testing and research aimed at identifying risk factors for various diseases. The integration of genetic data into preventive care not only enhances individual health decisions but also enables healthcare providers to develop targeted interventions tailored to an individual's genetic profile.

This preventive focus can lead to significant cost savings for healthcare systems by reducing the incidence of chronic diseases and minimizing the need for costly treatments. By catching potential health issues early through genetic screening, healthcare providers can implement interventions that lead to better health outcomes. As the trend toward preventive healthcare continues to gain momentum, the market for DNA and RNA banking services is poised for substantial growth. The increasing recognition of the importance of genetic insights in disease prevention positions biobanks as essential partners in the future of healthcare, driving innovation and improving population health on a global scale.

Segmental Insights

Type Insights

Based on the Type, in the Global DNA & RNA Banking Services Market, Processing Services are currently dominating, primarily due to their critical role in ensuring the quality and integrity of genetic materials. The processing phase encompasses the collection, isolation, purification, and analysis of DNA and RNA samples, which are essential steps in preparing these samples for subsequent storage and research applications. This phase is vital, as the quality of the processed samples directly influences the reliability of genetic analyses, making it a top priority for biobanks and research institutions.

The demand for high-quality processed samples is driven by the increasing focus on precision medicine and genetic research, where the accuracy of results is paramount. Processing services that employ advanced techniques and technologies, such as automation and next-generation sequencing (NGS), enhance the efficiency and reliability of sample preparation. As a result, many biopharmaceutical companies, research institutions, and clinical laboratories are investing heavily in high-quality processing services to support their innovative research initiatives.

Application Insights

Based on the application, in the Global DNA & RNA Banking Services Market, the Therapeutics, application segment is currently dominating. This dominance can be attributed to the increasing emphasis on personalized medicine, where understanding an individual's genetic makeup is essential for developing targeted therapies. Biopharmaceutical companies and research institutions are leveraging DNA and RNA banking services to obtain high-quality genetic materials, which are crucial for researching and developing novel therapeutics, including biologics and gene therapies.

The growing prevalence of genetic disorders and complex diseases, such as cancer, diabetes, and cardiovascular diseases, has intensified the focus on therapeutic development. By utilizing genetic data from biobanks, researchers can identify genetic mutations and biomarkers that contribute to disease progression. This information is instrumental in formulating tailored treatment plans that can significantly enhance patient outcomes. Advancements in technologies like CRISPR and gene editing are further driving the need for robust DNA and RNA samples, as these techniques rely heavily on accurate genetic information.

Regional Insights

North America is currently the dominant region in the Global DNA & RNA Banking Services Market. This dominance can be attributed to several factors that create a favorable environment for biobanking services. North America, particularly the United States, is home to a large number of leading research institutions, universities, and pharmaceutical companies. These entities invest significantly in genetic research, driving demand for DNA and RNA banking services. The availability of advanced technologies and facilities facilitates extensive research, including drug development and personalized medicine initiatives.

With a growing awareness of genetic disorders and the importance of genetic testing, there is an increasing demand for DNA and RNA samples for diagnostics and therapeutic development in North America. This trend is driving healthcare providers and research organizations to utilize biobanking services more extensively. The North American region benefits from substantial government funding and support for biomedical research. Initiatives from agencies such as the National Institutes of Health (NIH) and other public and private organizations promote genetic research, further boosting the need for reliable biobanking services.

Key Market Players

  • DNA Genotek Inc
  • EasyDNA
  • 23andMe, Inc.
  • Biobanking.com
  • US Biolab Corporation, Inc
  • ProteoGenex
  • Thermo Fisher Scientific, Inc.
  • deCODE genetics
  • Azenta Life Sciences
  • Infinity BiologiX LLC (Sampled)

Report Scope:

In this report, the Global DNA & RNA Banking Services Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

DNA & RNA Banking Services Market, By Type:

  • Transportation Service
  • Processing Service
  • Storage Service
  • Quality Control Service
  • Data Storage
  • Others

DNA & RNA Banking Services Market, By Application:

  • Therapeutics
  • Drug Discovery & Clinical Research
  • Clinical Diagnostics
  • Others

DNA & RNA Banking Services Market, By End Use:

  • Academic Research
  • Pharmaceutical & Biotechnology Companies
  • Hospitals & Diagnostic Centers
  • Others

DNA & RNA Banking Services Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global DNA & RNA Banking Services Market.

Available Customizations:

Global DNA & RNA Banking Services Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global DNA & RNA Banking Services Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Transportation Service, Processing Service, Storage Service, Quality Control Service, Data Storage, Others)
    • 5.2.2. By Application (Therapeutics, Drug Discovery & Clinical Research, Clinical Diagnostics, Others)
    • 5.2.3. By End Use (Academic Research, Pharmaceutical & Biotechnology Companies, Hospitals & Diagnostic Centers, Others)
    • 5.2.4. By Company (2024)
    • 5.2.5. By Region
  • 5.3. Market Map

6. North America DNA & RNA Banking Services Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Application
    • 6.2.3. By End Use
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States DNA & RNA Banking Services Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By End Use
    • 6.3.2. Mexico DNA & RNA Banking Services Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By End Use
    • 6.3.3. Canada DNA & RNA Banking Services Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By End Use

7. Europe DNA & RNA Banking Services Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Application
    • 7.2.3. By End Use
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France DNA & RNA Banking Services Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By End Use
    • 7.3.2. Germany DNA & RNA Banking Services Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By End Use
    • 7.3.3. United Kingdom DNA & RNA Banking Services Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By End Use
    • 7.3.4. Italy DNA & RNA Banking Services Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By End Use
    • 7.3.5. Spain DNA & RNA Banking Services Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By End Use

8. Asia-Pacific DNA & RNA Banking Services Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Application
    • 8.2.3. By End Use
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China DNA & RNA Banking Services Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By End Use
    • 8.3.2. India DNA & RNA Banking Services Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By End Use
    • 8.3.3. South Korea DNA & RNA Banking Services Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By End Use
    • 8.3.4. Japan DNA & RNA Banking Services Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By End Use
    • 8.3.5. Australia DNA & RNA Banking Services Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By End Use

9. South America DNA & RNA Banking Services Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Application
    • 9.2.3. By End Use
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil DNA & RNA Banking Services Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By End Use
    • 9.3.2. Argentina DNA & RNA Banking Services Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By End Use
    • 9.3.3. Colombia DNA & RNA Banking Services Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By End Use

10. Middle East and Africa DNA & RNA Banking Services Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Application
    • 10.2.3. By End Use
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa DNA & RNA Banking Services Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By End Use
    • 10.3.2. Saudi Arabia DNA & RNA Banking Services Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By End Use
    • 10.3.3. UAE DNA & RNA Banking Services Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By End Use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Porters Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Products

14. Competitive Landscape

  • 14.1. DNA Genotek Inc.
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Financials (As Reported)
    • 14.1.5. Recent Developments
    • 14.1.6. Key Personnel Details
    • 14.1.7. SWOT Analysis
  • 14.2. EasyDNA
  • 14.3. 23andMe, Inc.
  • 14.4. Biobanking.com
  • 14.5. US Biolab Corporation, Inc
  • 14.6. ProteoGenex
  • 14.7. Thermo Fisher Scientific, Inc.
  • 14.8. deCODE genetics
  • 14.9. Azenta Life Sciences
  • 14.10. Infinity BiologiX LLC (Sampled).

15. Strategic Recommendations

16. About Us & Disclaimer